Article Figures & Data
Figures
- Figure 1.
A. Number of interferon-γ (IFN-γ) enzyme-linked immunospot (ELISPOT) spot-forming units with varicella zoster virus (VZV) stimulation by timepoint for patients with systemic lupus erythematosus (SLE) and control subjects. Inset panel B displays the number of IFN-γ ELISPOT spot-forming units with phytohemagglutinin stimulation by timepoint for patients with SLE and control subjects. The median number of spots is displayed as a horizontal bar within the box plot with the interquartile range (IQR) ± range graphed. **Statistical significance using a Mann-Whitney U test with α = 0.05.
- Figure 2.
Median [interquartile range (IQR)] anti-varicella zoster virus (VZV) IgG index value at each timepoint for patients with systemic lupus erythematosus (SLE) and control subjects. *Statistical significance using a Mann-Whitney U test with α = 0.05.
Tables
Characteristics SLE Healthy n 10 10 % female 100 100 Age, yrs, mean (SD) 60.5 (5.4)* 55.3 (4.2) White, n 7 7 African American, n 3 3 History of shingles, n 4 2 Taking prednisone, n 4 0 Mean daily dose, mg 6.9 — Taking HCQ, n 7 0 Taking MTx, n 2 0 Baseline SLEDAI, median (range) 0 (0–2) — -
↵* p < 0.05 compared to healthy subjects. HCQ: hydroxychloroquine; MTX: methotrexate; SLE: systemic lupus erythematosus; SLEDAI: SLE Disease Activity Index.
-
SLE Healthy HZ, n 0 0 Serious adverse event, n 0 0 ISR (any), n 3 3 Erythema, tenderness, n 3 3 Vesicular lesions, n 0 0 2-week SLEDAI, median (range) 0 (0–3) — 6-week SLEDAI, median (range) 1 (0–3) — 12-week SLEDAI, median (range) 0 (0–3) — SLE flare, n 0 — -
ISR: injection site reaction; SLEDAI: Systemic Lupus Erythematosus Disease Activity Index; HZ: herpes zoster.
-
In this issue
